Health Care & Life Sciences » Biotechnology | Protalix BioTherapeutics Inc.

Protalix BioTherapeutics Inc.

Protalix BioTherapeutics Inc.
Stock Exchange NYSE
EPS
$0.18
Market Cap
$66.74 M
Shares Outstanding
148.3 M
Public Float
136.43 M

Profile

Address
2 Snunit Street
Carmiel HZ 21614
Israel
Employees -
Website http://www.protalix.com
Updated 07/08/2019
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications.

Financials

View All

Shlomo Yanai
Chairman
Moshe Manor
President, Chief Executive Officer & Director